Metformin Ratiopharm (Metformin)

Metformin acts primarily on the liver to suppress gluconeogenesis, thereby decreasing the amount of glucose released into the bloodstream. It also enhances peripheral insulin sensitivity, promoting greater glucose uptake by muscle and fat cells, and modestly reduces intestinal glucose absorption.

The appropriate dose of Metformin Ratiopharm is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformin may be used during pregnancy only when the potential benefits justify the potential risks to the fetus, and it is generally considered safe in certain gestational diabetes cases. Use while breastfeeding should be discussed with a healthcare provider, as small amounts are excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is often the first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycaemia when used alone. Other classes, such as sulfonylureas or insulin, may cause weight gain or hypoglycaemia and are typically added when metformin alone does not achieve target glucose levels.

Metformin Ratiopharm tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Metformin Ratiopharm is taken orally, usually with meals to minimise gastrointestinal upset. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with significant renal or hepatic impairment, severe infection, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies that may affect kidney function. Clinicians should evaluate each patient’s medical history before prescribing.